A pilot analytic study of a research-level, lower-cost human papillomavirus 16, 18, and 45 test

Journal of Virological Methods

Volumn 176, Issue 1-2, 2011, Pages 112-114

  Yang, Hannah P ^a   Walmer, David K ^b,c   Merisier, Delson ^b,c   Gage, Julia C ^a   Bell, Laura ^d   Rangwala, Sameera ^d   Shrestha, Niwashin ^d   Kobayashi, Lori ^d   Eder, Paul S ^d   Castle, Philip E ^e  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Family Health Ministries   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d QIAGEN North America   (United States)

^e American Society for Clinical Pathology Institute   (United States)

Author keywords

Cervical cancer; HPV genotypes; HPV test; Human papillomavirus (HPV)

Indexed keywords

VIRUS DNA;

ARTICLE; CARCINOGENICITY; COLPOSCOPY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DNA SEQUENCE; FALSE POSITIVE RESULT; FEMALE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 45; MAJOR CLINICAL STUDY; MULTIPLEX POLYMERASE CHAIN REACTION; PATIENT REFERRAL; PILOT STUDY; PRIORITY JOURNAL; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; SCREENING TEST; SENSITIVITY AND SPECIFICITY; VIRUS DETECTION;

CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; COLPOSCOPY; DNA, VIRAL; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; PAPILLOMAVIRUS INFECTIONS; PILOT PROJECTS; POLYMERASE CHAIN REACTION; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS - 16; HUMAN PAPILLOMAVIRUS TYPE 16;

EID: 79960601632     PISSN: 01660934     EISSN: 18790984     Source Type: Journal    
DOI: 10.1016/j.jviromet.2011.05.024     Document Type: Article

References (19)

1. Berkhof J., Bulkmans N.W., Bleeker M.C., Bulk S., Snijders P.J., Voorhorst F.J., Meijer C.J. Human papillomavirus type-specific 18-month risk of high-grade cervical intraepithelial neoplasia in women with a normal or borderline/mildly dyskaryotic smear. Cancer Epidemiol. Biomarkers Prev. 2006, 15:1268-1273.
2. Bulkmans N.W., Berkhof J., Bulk S., Bleeker M.C., van Kemenade F.J., Rozendaal L., Snijders P.J., Meijer C.J. High-risk HPV type-specific clearance rates in cervical screening. Br. J. Cancer 2007, 96:1419-1424.
3. Clifford G.M., Gallus S., Herrero R., Munoz N., Snijders P.J., Vaccarella S., Anh P.T., Ferreccio C., Hieu N.T., Matos E., Molano M., Rajkumar R., Ronco G., de Sanjose S., Shin H.R., Sukvirach S., Thomas J.O., Tunsakul S., Meijer C.J., Franceschi S. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005, 366:991-998.
4. Coutlee F., Gravitt P., Kornegay J., Hankins C., Richardson H., Lapointe N., Voyer H., Franco E. Use of PGMY primers in L1 consensus PCR improves detection of human papillomavirus DNA in genital samples. J. Clin. Microbiol. 2002, 40:902-907.
5. Cox J.T. History of the use of HPV testing in cervical screening and in the management of abnormal cervical screening results. J. Clin. Virol. 2009, 45(Suppl. 1):S3-S12.
6. Cuzick J., Arbyn M., Sankaranarayanan R., Tsu V., Ronco G., Mayrand M.H., Dillner J., Meijer C.J. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 2008, 26(Suppl. 10):K29-K41.
7. de Roda Husman A.M., Walboomers J.M., van den Brule A.J., Meijer C.J., Snijders P.J. The use of general primers GP5 and GP6 elongated at their 3' ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J. Gen. Virol. 1995, 76(Pt 4):1057-1062.
8. de Sanjose S., Diaz M., Castellsague X., Clifford G., Bruni L., Munoz N., Bosch F.X. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect. Dis. 2007, 7:453-459.
9. Denny L., Kuhn L., Hu C.C., Tsai W.Y., Wright T.C. Human papillomavirus-based cervical cancer prevention: long-term results of a randomized screening trial. J. Natl. Cancer Inst. 2010, 102:1557-1567.
10. Gage J.C., Castle P.E. Preventing cervical cancer globally by acting locally: if not now, when?. J. Natl. Cancer Inst. 2010, 102:1524-1527.
11. Garcia M., Jemal A., Ward E.M., Center M.M., Hao Y., Siegel R.I., Thun M.J. Global Cancer Facts & Figures 2007 2007, American Cancer Society, Atlanta, GA.
12. IARC Cervix Cancer Screening 2005, IARC Press.
13. Khan M.J., Castle P.E., Lorincz A.T., Wacholder S., Sherman M., Scott D.R., Rush B.B., Glass A.G., Schiffman M. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J. Natl. Cancer Inst. 2005, 97:1072-1079.
14. Munoz N., Bosch F.X., de Sanjose S., Herrero R., Castellsague X., Shah K.V., Snijders P.J., Meijer C.J. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 2003, 348:518-527.
15. Nazarenko I., Kobayashi L., Giles J., Fishman C., Chen G., Lorincz A. A novel method of HPV genotyping using Hybrid Capture sample preparation method combined with GP5+/6+ PCR and multiplex detection on Luminex XMAP. J. Virol. Methods 2008, 154:76-81.
16. Poljak M., Brencic A., Seme K., Vince A., Marin I.J. Comparative evaluation of first- and second-generation digene hybrid capture assays for detection of human papillomaviruses associated with high or intermediate risk for cervical cancer. J. Clin. Microbiol. 1999, 37:796-797.
17. Qiao Y.L., Sellors J.W., Eder P.S., Bao Y.P., Lim J.M., Zhao F.H., Weigl B., Zhang W.H., Peck R.B., Li L., Chen F., Pan Q.J., Lorincz A.T. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol. 2008, 9:929-936.
18. Schiffman M.H., Castle P. Epidemiologic studies of a necessary causal risk factor: human papillomavirus infection and cervical neoplasia. J. Natl. Cancer Inst. 2003, 95:E2.
19. Wright J.D., Li J., Gerhard D.S., Zhang Z., Huettner P.C., Powell M.A., Gibb R.K., Herzog T.J., Mutch D.G., Trinkaus K.M., Rader J.S. Human papillomavirus type and tobacco use as predictors of survival in early stage cervical carcinoma. Gynecol. Oncol. 2005, 98:84-91.